Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Adeona Pharmaceuticals, Inc. announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing. Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab subsidiary.

15 Jun 2010

Study: Mentally active lifestyle may protect against memory and learning problems in MS

A new study shows that a mentally active lifestyle may protect against the memory and learning problems that often occur in multiple sclerosis. The study is published in the June 15, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

MultiCell Technologies, Inc. has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

Phase II study results of riociguat for CTEPH and PAH published online

Bayer HealthCare Pharmaceuticals, Inc. today announced that the study "Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study" was published online this week by the European Respiratory Journal. Results of this study to assess the safety, tolerability and the feasibility of individual dose titration of riociguat were previously presented at the 2009 International Conference of the American Thoracic Society.

11 Jun 2010

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

An emerging arm of molecular biology is introducing a new interpretation of traditional concepts of human disease, explains an article published today in Nature. According to author Dr. Arturas Petronis at the Centre for Addiction and Mental Health, the emerging science of epigenetics is offering new insights at the crossroads of genes and the environment, or nature and nurture. Dr. Petronis is head of the Krembil Family Epigenetics Laboratory at CAMH and an international expert in the field.

11 Jun 2010

Universal Bioenergy, NDR Energy Group sponsor charitable event to raise funds for National Multiple Sclerosis Society

Universal Bioenergy Inc., an alternative energy company, and NDR Energy Group, announced today that they are sponsoring a major charitable event to help raise funds for the National Multiple Sclerosis Society.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

2010 Independence Expo to promote active living and independence for aged and disabled Americans

United Spinal Association presents the 2010 Independence Expo – Long Island, the region's premier lifestyle-enhancing Expo designed to promote active living and independence for all people with disabilities and aging Americans.

10 Jun 2010

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.

10 Jun 2010

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.

10 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Men with MS may require education, support to manage their disease and therapy: Research

New research co-published by Saint Louis University and Express Scripts, Inc., suggests that men with multiple sclerosis may require more education and support to manage their disease and therapy than women with MS. Men also may benefit from more targeted adherence interventions.

10 Jun 2010

New AAN guideline provides step-by-step process for determining brain death in adults

In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

9 Jun 2010

CXCR4 protein restores brain damage in multiple sclerosis patients

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis (MS) and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

Biogen, Elan launch My MS Health, a web-based PRO research program

Biogen Idec and Elan Corporation, plc, in collaboration with EPI-Q, Inc. and Avatar International, LLC, today announced the launch of My MS Health, a first-of-its-kind, web-based, patient-reported outcomes research program. My MS Health is designed to track and provide instant reports on patient function and quality of life using validated measures over time.

9 Jun 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Study: Mentally active lifestyle may protect against memory and learning problems in MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

National MS Society commits over $2.4M to support 7 CCSVI research projects

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

Phase II study results of riociguat for CTEPH and PAH published online

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

Universal Bioenergy, NDR Energy Group sponsor charitable event to raise funds for National Multiple Sclerosis Society

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

2010 Independence Expo to promote active living and independence for aged and disabled Americans

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

Caregiver's guide on avoiding life-threatening swallowing problems

Men with MS may require education, support to manage their disease and therapy: Research

New AAN guideline provides step-by-step process for determining brain death in adults

CXCR4 protein restores brain damage in multiple sclerosis patients

Blood vessel-blocking drug slows prostate cancer progression: Experts

Biogen, Elan launch My MS Health, a web-based PRO research program

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in